Positive outcomes for apalutamide in the treatment of mHSPC

According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …

Apalutamide (Erleada) approved in EU for treatment of nmCRPC

Yesterday, Janssen Pharmaceuticals announced the approval of apalutamide (Erleada) by the European Commission (EC) for the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC) who are at high risk for development of metastatic disease. … READ MORE …

Germline BRCA2 mutations and management of mCRPC

A newly published paper in the Journal of Clinical Oncology has confirmed — based on a prospective study (as opposed to retrospective data) — that there is a strong risk association between a germline mutation of the BRCA2 gene and risk for metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

ADT + enzalutamide in mHSPC … outcome of the ARCHES trial

Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Is there a subset of CRPC patients who may respond well to checkpoint inhibition?

A paper in the journal Oncotarget has suggested that patients who have progressed on treatment with enzalutamide (Xtandi) may be good candidates for treatment with one of the checkpoint inhibitors like pembrolizumab (Keytruda), nivolumab (Opdivo), or even ipilimumab (Yervoy). … READ MORE …

Topsalycin in the treatment of prostate cancer: an update

Some 3 years ago we first commented on a Phase II trial of a drug now called topsalycin (but then known as PRX302) in the treatment of low- to intermediate-risk, localized prostate cancer. … READ MORE …

MFS as an endpoint in clinical trials

Earlier this year, two drugs (apalutamide/Erleada and enzalutamide/Xtandi) were each approved for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC) based on the use of metastasis-free survival (MFS) as the study endpoint in clinical trials. … READ MORE …